These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 28251811)

  • 1. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
    Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion:
    Pielen A; Feltgen N; Hattenbach LO; Hoerauf H; Bertelmann T; Quiering C; Vögeler J; Priglinger S; Lang GE; Schmitz-Valckenberg S; Wolf A; Rehak M
    Curr Eye Res; 2020 May; 45(5):604-614. PubMed ID: 31665935
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.
    Hoerauf H; Feltgen N; Weiss C; Paulus EM; Schmitz-Valckenberg S; Pielen A; Puri P; Berk H; Eter N; Wiedemann P; Lang GE; Rehak M; Wolf A; Bertelmann T; Hattenbach LO;
    Am J Ophthalmol; 2016 Sep; 169():258-267. PubMed ID: 27163237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
    Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
    Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
    Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
    Yuksel B; Karti O; Celik O; Kerci SG; Kusbeci T
    Clin Exp Optom; 2018 Jan; 101(1):116-122. PubMed ID: 28922697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
    Meng L; Yang M; Jiang X; Li Y; Han X
    Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
    Bandello F; Augustin A; Tufail A; Leaback R
    Eur J Ophthalmol; 2018 Nov; 28(6):697-705. PubMed ID: 29631435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
    Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.
    Moon SY; Cho KH; Woo SJ; Park SP; Kim YK
    Korean J Ophthalmol; 2018 Feb; 32(1):29-37. PubMed ID: 29376223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion.
    Kim M; Lee DH; Byeon SH; Koh HJ; Kim SS; Lee SC
    Br J Ophthalmol; 2015 Sep; 99(9):1271-6. PubMed ID: 25777815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.